Nov 12, 2026, 1:00 PMPharmaceuticals
Drugmakers Bet Billions on Vaccines as Moderna and Merck Data Show Promise
Moderna and Merck’s experimental cancer-vaccine data, plus research linking shingles vaccination to delayed dementia, support continued vaccine investment.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on November 12, 2026, that major drug companies are committing billions of dollars to vaccines despite the political environment. The extract identifies Moderna and Merck as examples but provides no investment breakdown, timeline or policy specifics.
The support cited is promising data for Moderna and Merck’s experimental cancer vaccine, alongside research suggesting shingles vaccination can delay dementia. These findings strengthen the case for vaccine research, but the limited feed omits trial results, development milestones and details about the shingles vaccine.
Positives
- Promising data support continued development of Moderna and Merck’s experimental cancer vaccine.
- Research suggests shingles vaccination can delay dementia, indicating a potential benefit beyond preventing shingles.
- Billions of dollars are being committed to vaccines by major drug companies despite the political environment.
Risks & concerns
- Moderna and Merck’s cancer vaccine remains experimental, and the extract provides no development timeline.
- The limited feed includes no trial size, efficacy percentage, safety findings or statistical results for the cancer vaccine.
- The source does not identify the shingles vaccine, its manufacturer or the strength of the dementia research.
- The political environment is presented as an obstacle, but the extract provides no policy or regulatory details.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/the-worlds-most-sophisticated-drug-companies-are-putting-billions-into-vaccines-despite-the-political-environment-8dcbf276?mod=mw_rss_topstories
Read full article

